Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperdal Consta in Early Onset Psychosis
NCT00369239Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2006
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of risperidone in schizophrenia, schizoaffective disorder and psychotic disorders, sponsored by Janssen Pharmaceutical. Primary endpoint: Treatment Response based on Premorbid Functioning at 6 months. Started Mar 2006; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorderpsychotic disorders
Beyond the preview
Go deeper on NCT00369239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369239.